Sitava Tablet 25 mg (Sitagliptin Hydrochloride Monohydrate)
Sitagliptin Hydrochloride Hydrate 28.35mg
Tablet · Prescription medication
Aprogen Pharmaceuticals, Co., Ltd.
MFDS item code 202004106 · Approved 2020.05.29
This product's status changed to Expired on 2025.05.29. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication is used to help control blood sugar levels in patients with type 2 diabetes. It can be administered alone or in combination with dietary and exercise therapy, and if the monotherapy is insufficient during initial treatment, it is combined with metformin. Additionally, it can be used to enhance effectiveness in patients having difficulty with blood sugar control, whether administered alone or in combination with other diabetes medications such as sulfonylureas, thiazolidinediones, and insulin. This combination therapy helps to further improve blood sugar control.
This medicine is administered at 100 mg once daily as monotherapy or combination therapy, and the maximum daily dose is 100 mg. This medicine may be taken regardless of meals. When this medicine is administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). Patients with renal impairment Because dosage adjustment based on renal function is required, evaluation of renal function is recommended before treatment with this medicine and periodically thereafter. 1. No dose adjustment is required in patients with mild renal impairment (glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dose adjustment is required in patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. Administer 50 mg once daily to patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2). 4. Administer 25 mg once daily to patients with severe renal impairment (glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). This medicine may be administered regardless of the timing of dialysis.
This medication can rarely cause serious allergic reactions. Such reactions may appear within the first 3 months after starting the medication, so if symptoms like skin rash or difficulty breathing occur, it is important to stop taking the drug immediately and consult a doctor. This medication can cause a disease known as pancreatitis, which is inflammation of the pancreas, so if symptoms like abdominal pain or vomiting occur, alert healthcare personnel immediately. This medication should not be used in patients with type 1 diabetes, diabetic ketoacidosis, or those allergic to this drug or its components. Patients with impaired kidney function may require a dose adjustment, and it is important to undergo regular kidney function tests. During treatment with this medication, symptoms similar to a cold, headache, indigestion, diarrhea may occur. Additionally, symptoms of hypoglycemia may appear, especially when taken with insulin or sulfonylureas, so caution is needed. The risk of hypoglycemia may increase when this medication is taken with other hypoglycemic agents; therefore, adjusting the doses of other medications may be necessary. Rarely, symptoms like arthralgia or blisters on the skin have been reported, so if these symptoms appear, consult a physician immediately. This medication is not recommended for use during pregnancy or breastfeeding, and its safety for children under 18 years old has not been established. In cases of overdose, general supportive care and, if necessary, blood dialysis may be considered. This medication is known not to significantly affect cardiovascular safety; however, if any abnormal symptoms occur during treatment, consult a healthcare provider immediately.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to protect it from air or moisture, and it is best to keep it at room temperature between 1 and 30 degrees Celsius. Storing it this way helps maintain the effectiveness of the medication for a longer time.
Pink, round, double convex film-coated tablet
28 tablets) 14 tablets/PTP(x2), 30 tablets) 10 tablets/PTP(x3)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Sitagliptin Hydrochloride Hydrate 28.35mg
Tablet · Prescription medication
Aprogen Pharmaceuticals, Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Korea United Pharm., Co., Ltd.

Sitagliptin Hydrochloride Hydrate 128.5mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 128.5mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 28.35mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.

Sitagliptin Hydrochloride Hydrate 56.7mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.